4-氨基-1-苯基-1H-吡唑-3-甲酸 | 64299-26-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氨基-1-苯基-1H-吡唑-3-甲酸
• 中文别名: 4-氨基-1-苯基-1H-吡唑-3-羧酸
• 英文名称: 4-amino-1-phenyl-1H-pyrazole-3-carboxylic acid
• 英文别名: 4-Amino-1-phenylpyrazol-3-carbonsaeure；4-Amino-1-phenyl-1H-pyrazole-3-carboxylic acid；4-amino-1-phenylpyrazole-3-carboxylic acid
• CAS: 64299-26-9
• 化学式: C₁₀H₉N₃O₂
• 分子量: 203.2
• InChiKey: YAAFWVJWMRAZOW-UHFFFAOYSA-N

物化性质

• 密度：
  1.41

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氨基-1-苯基-1H-吡唑-3-甲酸 、 原丙酸三乙酯 在 ammonium acetate 作用下， 反应 0.25h， 以30%的产率得到5-ethyl-2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
  参考文献：
  名称：

  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A₃ Adenosine Receptor Antagonists: New Insights into the Receptor−Antagonist Recognition

  摘要：

  A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic Scaffold (R-5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K-i = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose it novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) Selectivity profiles of these new antagonists.

  DOI：

  10.1021/jm900718w
• 作为产物：
  描述：

  4-amino-1-phenyl-1H-pyrazole-3,5-dicarboxylic acid 在 磷酸 作用下， 反应 0.75h， 以60%的产率得到4-氨基-1-苯基-1H-吡唑-3-甲酸
  参考文献：
  名称：

  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A₃ Adenosine Receptor Antagonists: New Insights into the Receptor−Antagonist Recognition

  摘要：

  A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic Scaffold (R-5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K-i = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose it novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) Selectivity profiles of these new antagonists.

  DOI：

  10.1021/jm900718w

文献信息

• Hetero-halo inhibitors of histone deacetylase
  申请人：Alkermes, Inc.

  公开号：US10919902B2

  公开（公告）日：2021-02-16

  This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

  本发明提供的化合物是 HDAC2 的抑制剂。这些化合物（例如，根据式I、II或化合物100-128中的任一种或表2或表3中的任一种）相应地可用于治疗、减轻或预防受试者的病症，如神经系统疾病、记忆或认知功能障碍或损伤、消退性学习障碍、真菌疾病或感染、炎症性疾病、血液病或肿瘤性疾病，或用于改善记忆或治疗、减轻或预防记忆丧失或损伤。
• GEWALD K.; CALDERON O., MONATSH. CHEM. <MOCH-AP>, 1977, 108, NO 3, 611-616
  作者：GEWALD K.、 CALDERON O.

  DOI：——

  日期：——
• HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE
  申请人：Rodin Therapeutics, Inc.

  公开号：US20180194769A1

  公开（公告）日：2018-07-12

  This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
• 2-Phenylpyrazolo[4,3-<i>d</i>]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A₃ Adenosine Receptor Antagonists: New Insights into the Receptor−Antagonist Recognition
  作者：Ombretta Lenzi、Vittoria Colotta、Daniela Catarzi、Flavia Varano、Daniela Poli、Guido Filacchioni、Katia Varani、Fabrizio Vincenzi、Pier Andrea Borea、Silvia Paoletta、Erika Morizzo、Stefano Moro

  DOI：10.1021/jm900718w

  日期：2009.12.10

  A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic Scaffold (R-5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K-i = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose it novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) Selectivity profiles of these new antagonists.